Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Feb 06, 2004 12:48am
460 Views
Post# 7011417

RE: Investors Relax

RE: Investors Relaxoldpro in case you forgot, this is what you posted over 2 years ago, re: onc i am anticipating onc to motor to the $10.50 range before being halted. when trading resumes i expect $12.+++++++ FASTEN YOUR SEATBELTS WE ARE READY FOR BLASTOFF!! https://www.stockhouse.ca/bullboards/viewmessage.asp?no=4475128&tableid=2 that was only a month before pfizer officially dropped reovirus development for animals. your timing so far seems to have been impeccable - perhaps a very good contrarian indicator? the real problem here is all the unsupported speculation and unconfirmed apparent "leaks" to posters that share these "rumours" about news to be released "soon". since the company refuses to officially update its shareholders but prefers to keep them in the dark, yet apparently unofficially "leak" that "news is pending" to a select few, well, i don't think its too difficult to figure out there is a serious credibility problem. the wild swings in price, imo, are directly attributable to a management unprepared and/or unwilling to properly and adequately disclose the status of progress of their work to shareholders on a regular basis. the lack of official news directly leads to misinformation, unsupported speculation & rumour, innuendo, and a very poorly informed and inefficient market that leads directly to wild price swings, greater manipulation, and loss of credibility and confidence in management. these guys may lucked upon the fact that reolysin may be an important breakthru in cancer treatment, but they have shown to date, they really don't know what to do with it. in fact, with the retreat to their "cone of silence" bunker, they apparently don't want anyone to know what is going on, but the few they choose to disclose tidbits to. imo, that leaves shareholders only 1 remaining piece of information available to try and determine what is going on, and that is the volume. obviously increasing volume with increasing price is a strong indication of buying interest, and conversely, a decreasing price with even greater volume is a strong indication of considerable weakness. when these two occurences happen over consecutive trading days, it strongly suggests manipulation - that the company at least implicitly allows and even encourages by its lack of giving a regular account to shareholders of the status of their apparently ongoing trials. you can blame it on daytraders, speculators, TA enthusiasts, shorters, blah, blah, blah, blah, but if you do, you miss the real culprit, imo. if the company simply disclosed where it is at with the prostate, glio & systemic trials, there would be much less room for rumour, speculation and above all, manipulation. then again, these are the same guys hired wayne schnarr, the infamous "$50 target" guy from cannacord, whose hiring warranted a pr from onc, with BT saying "I have wanted to work directly with Dr. Schnarr for some time and am delighted to have the opportunity to do so.", yet whose departure apparently occurred under a cloak of darkness. these guys are in way over their heads, and i think the bigger miracle will be if these guys are able to get reolysin commercialized, than if it actually works.
Bullboard Posts